검색어: cytopeni (덴마크어 - 영어)

cytopeni
hypersensitivity

cytopeni,
, leucopenia,

refraktÆr cytopeni
refractory cytopenia

antistof-cytopeni
antibody cytopenia

trombo -cytopeni anæmi
thrombocytopenia

anæmi, trombo- cytopeni
anaemia, thrombo- cytopenia

hvis cytopeni recidiverer, gentages trin
if recurrence of cytopenia, repeat step 1

undersøg om cytopeni er relateret til
check whether cytopenia is related to leukaemia (marrow aspirate or biopsy) .

hæmatologiske bivirkninger herunder klinisk signifikant cytopeni (f. eks. ke
adverse events of the haematologic system, including medically significant cytopoenia (e. g. rod

hvis cytopeni vedvarer i 2 uger, reducér dosis yderligere til 300 mg.
if cytopenia persists for 2 weeks, reduce further to 300 mg.

hvis cytopeni ikke er leukæmirelateret, reducér glivec-dosis til 400 mg.
if cytopenia is unrelated to leukaemia, reduce dose of glivec to 400 mg.

hvis cytopeni vedvarer i 2 uger, reducér dosis yderligere til 200 mg/m2.
if cytopenia persists for 2 weeks, reduce further to 200 mg/m2.

1 undersøg om cytopeni er relateret til leukæmi (marvaspirat eller biopsi).
check if cytopenia is related to leukaemia (marrow aspirate or biopsy).

hvis cytopeni ikke er leukæmirelateret, reducér imatinib teva-dosis til 260 mg/m2.
if cytopenia is unrelated to leukaemia, reduce dose of imatinib to 260 mg/m2.

undersøg om cytopeni er relateret til leukæmi (marv-aspirat eller biopsi).
check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).

febril neutropeni, pancytopeni, granulocytopeni, thrombo- cytopeni, leukopeni, hæmolytisk anæmi,
febrile neutropenia, pancytopenia, granulocytopenia, thrombocytopenia, leukopenia, haemolytic anaemia, international normalised ratio (inr)

derfor fik alle patienter omfattende cytopeni: leukopeni 96%, trombocytopeni 94% og anæmi 88%.
therefore all patients experienced profound cytopenia: leukopenia 96%, thrombocytopenia 94%, and anemia 88%.

hæmatologiske bivirkninger herunder klinisk signifikant cytopeni (f.eks. trombocytopeni, leukopeni) er rapporteret efter behandling med humira.
adverse events of the haematologic system, including medically significant cytopoenia (e.g. thrombocytopaenia, leucopaenia) have been reported with humira.

ved cml var cytopenier (trombocytopeni, neutropeni og anæmi) vedvarende fund.
in cml, cytopenias (thrombocytopenia, neutropenia, and anaemia) were a consistent finding.